Click on image to view larger version.

Figure 1 Acute Catheterization and Urgent Intervention Triage Strategy Trial (ACUITY): 30-day composite net clinical benefit (death, myocardial infarction, revascularization for ischemia, or major bleeding), showing superiority of bivalirudin alone versus heparin plus glycoprotein (GP) IIb/IIIa inhibitors (p = 0.015). Combination of bivalirudin and GP IIb/IIIa inhibitors was noninferior to heparin plus GP IIb/IIIa inhibitors.